Altria Group stock has delivered a strong 134.4% return over the past 5 years, and the latest intrinsic value checks using a Discounted Cash Flow (DCF) approach currently point to the shares trading at a discount of 43.7% to that estimate.

• Over 5 years Altria Group has returned 134.4%, which puts current valuation in focus after a solid period for long term holders.
• Recent FDA proposals that may tighten oversight of foreign tobacco manufacturers can support Altria Group's pricing power, while ongoing regulatory and legal risks around tobacco products remain a key overhang for how investors value those future cash flows.
• Altria Group screens as undervalued on both the intrinsic value work and earnings multiples, yet its broader checks are mixed since it only scores 4 out of 6 on valuation.

The stock's next move may depend on whether the current discount to intrinsic value and multiples leaves enough margin of safety after such a strong multi year return profile.

Does Altria Group Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here is based on Altria Group's projected free cash flows to equity over a two stage period. For the latest twelve months, Altria Group generated about $8.7b in free cash flow, and the model assumes these cash flows continue to grow rather than shrink. On that basis, the DCF points to an estimated intrinsic value of about $133 per share.

This sits well above the current share price, which implies roughly a 43.7% discount to the modelled value and indicates the market is valuing Altria Group's cash generation cautiously. Because the recent FDA proposal would increase oversight of foreign manufacturers, the added regulatory focus provides one possible explanation for why some investors see room for the current price to move closer to what the cash flows support over time.

Overall, the Discounted Cash Flow work indicates Altria Group stock currently appears undervalued relative to its modelled cash flows.

Our Discounted Cash Flow (DCF) analysis suggests Altria Group is undervalued by 43.7%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.

Does Altria Group Look Undervalued on Earnings?

The P/E ratio is a useful yardstick for Altria Group because earnings remain a key anchor for how investors value mature tobacco companies.

Altria Group currently trades on a P/E of about 15.6x. That sits above the Tobacco industry average of about 11.8x, yet it is below the broader peer group average of around 27.3x. The tailored fair P/E ratio for Altria Group is estimated at roughly 20.3x, which is higher than where the stock trades today.

This gap to the fair ratio suggests the market is pricing Altria Group at a discount to what this framework implies based on its size, margins and risk profile. The stock screens as undervalued on earnings even though it already carries a premium to the sector average, which points to investors being relatively cautious about its earnings power.

On the P/E multiple alone, Altria Group stock looks undervalued compared with the fair ratio that the model suggests.

The Altria Group Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Altria Group sit between the valuation work above and the real world assumptions that would need to hold for a different share price to make sense. Narratives explain what would need to happen to Altria Group's future growth, margins and earnings for the stock to be worth significantly more or less than it is today. This allows you to see the future that each number depends on and track whether it is playing out. These can be found on Simply Wall St's Community page.

One of the top community narratives on Altria Group: 6% overvalued

"Market challenges from illicit e-vapor products and synthetic nicotine competition could hinder revenue growth and impact market share in key segments."

Do you think there's more to the story for Altria Group? Head over to our Community to see what others are saying!

The Bottom Line

Altria Group screens as undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and on its P/E multiple, although the mixed broader checks suggest the discount is not a simple mispricing. The crux is whether Altria Group can keep converting its earnings into reliable cash flows in the face of regulatory and legal pressure on tobacco and related products. For investors, the key question is whether the current discount compensates enough for those ongoing risks, or whether it signals a potential value trap if regulatory headwinds intensify.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.